Details of the Drug

General Information of Drug (ID: DMDEZI3)

Drug Name

Pegvisomant

Synonyms

Somavent; Pegvisomant (genetical recombination); Somavent (TN); Somavert (TN); Pegvisomant (USAN/INN); Pegvisomant (genetical recombination) (JAN)

Indication

Disease Entry	ICD 11	Status	REF
Acromegaly	5A60.0	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Anabolic Agents

Affected Organisms

Humans and other mammals

ATC Code

H01AX01: Pegvisomant

H01AX: Other anterior pituitary lobe hormones and analogues

H01A: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES

H01: PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES

H: SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

Sequence

FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPT
PSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEG
IQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIV
QCRSVEGSCGF

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 6 days [2]
Vd: The volume of distribution (Vd) of drug is 7 L []

Cross-matching ID

UNII: N824AOU5XV
DrugBank ID: DB00082
TTD ID: D0D6VE

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Growth hormone receptor (GHR)	TTKMAZ6	GHR_HUMAN	Antagonist	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7485).
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3	Growth hormone receptor antagonist treatment reduces exercise performance in young males. J Clin Endocrinol Metab. 2009 Sep;94(9):3265-72.